Breast Cancer
Tests
There are 13 Tests in this Category.
Breast Markers by Immunohistochemistry
AssociationsI AKT: Akt, protein kinase
I BRST 2: Cytokeratin 5, p63, CK8/18 breast cocktail
I BCL2: BCL2 follicular lymphoma, apoptosis inhibiting protein
I BER EP: Epithelial antigen (BER-EP4)
I CATHD: Cathepsin D
I CD117: c-kit, myeloid and mast cell (CD11 ...
MethodologyImmunohistochemistry
Cancer Antigen 15-3
Test CodeCA153
AssociationsBreast cancer
MethodologyChemiluminescent Immunoassay
CA 15-3 is performed by Ascendant Medical Laboratory
Cancer Antigen 27-29
Test CodeC2729
AssociationsBreast cancer
MethodologyChemiluminescent Immunoassay
CA 27-29 is performed by Ascendant Medical Laboratory
Carcinoembryonic Antigen
Test CodeCEA
AssociationsColorectal, lung, breast, ovary, uterus
MethodologyChemiluminescent Immunoassay
CEA is performed by Ascendant Medical Laboratory
Cell Cycle Analysis; DNA Ploidy and S Phase
Test CodePLOIDY
AssociationsBreast cancer, Non-small cell lung carcinoma, Bladder cancer
MethodologyFlow cytometry analysis
CellSearch™ - Circulating Tumor Cell Test Featured
Test CodeCELLSEARCH
AssociationsMetastatic breast, colorectal and prostate cancer
MethodologyImmunomagnetic selection and immunofluorescence
EGFR 7p12 Amplification
Test CodeF EGFR
AssociationsBreast, lung and colon cancer
MethodologyFluorescence in situ Hybridization (FISH)
EGFR Mutation Comprehensive Analysis Exon 18-21
Test CodeP EGFR
AssociationsNSCLC,Non Small-cell Lung Cancer,Response to EGFR tyrosine kinase inhibitors; Gefitinib Erlotinib, IRESSA, Tarceva Responsiveness in NSCLC
MethodologyReal-time Polymerase chain reaction for exon 18-21.
EGFR mutation is a referred test.
Epidermal Growth Factor Receptors (HER1) by IHC
Test CodeI HER1
AssociationsPrognostic marker
Overexpressed in breast cancer, lung, brain, bladder, gastric, esophagus, cervix, ovary and endometrium.
MethodologyImmunohistochemistry
CONFIRM™ anti-Epidermal Growth Factor Receptor
(3C6) Primary Antibody.
Estrogen Progesterone Receptors by IHC
Test CodeI ERPR
AssociationsBreast cancer
MethodologyImmunohistochemistry
CONFIRM™ anti-Estrogen Receptor (clone SP1)Primary Antibody
CONFIRM anti-Progesterone Receptor (clone 1E2) Primary Antibody
HER2 by Immunohistochemistry
Test CodeI HER2 or I HER2 TC
AssociationsBreast cancer, Herceptin
MethodologyImmunohistochemistry
HER2/neu PathVysion®
Test CodeF HER2
AssociationsBreast cancer
MethodologyFluorescence in situ Hybridization (FISH)
PTEN/CEP10 deletion 10q23.3
Test CodeF PTEN
AssociationsBreast cancer, endometrial carcimomas, glioblastoma
MethodologyFluorescence in situ Hybridization (FISH)
